DTPa-HBV-IPVHib vaccine (infanrix hexa™): A review of its use as primary and booster vaccination

Drugs

Volumn 70, Issue 8, 2010, Pages 1021-1058

  Dhillon, Sohita ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Children; Diphtheria; Haemophilus infections; Hepatitis B; Hib DTaP hepatitis B poliovirus vaccine; Immunogenicity; Infants; Pertussis; Poliomyelitis

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B SURFACE ANTIGEN; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; PNEUMOCOCCUS VACCINE; PRIORIX TETRA; RECOMBINANT HEPATITIS B VACCINE; ROTAVIRUS VACCINE; SYNFLORIX; UNCLASSIFIED DRUG; HAEMOPHILUS VACCINE; POLIOMYELITIS VACCINE; VACCINE;

ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; BRONCHITIS; CLINICAL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; CONVULSION; CRYING; DIARRHEA; DIPHTHERIA; DROWSINESS; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; ENCEPHALOMYELITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEBRILE CONVULSION; FEVER; GASTROENTERITIS; GEOMETRY; GUILLAIN BARRE SYNDROME; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; PERTUSSIS; POLIOMYELITIS; PREMATURITY; RASH; RESTLESSNESS; REVIEW; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN REDNESS; SUDDEN DEATH; TERM BIRTH; TETANUS; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; WORLD HEALTH ORGANIZATION; CHILD; IMMUNOLOGY; INFANT; NEWBORN; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

HAEMOPHILUS; HAEMOPHILUS INFLUENZAE SEROTYPE B; HEPATITIS B VIRUS; POLIOVIRUS;

CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; INFANT, NEWBORN; POLIOVIRUS VACCINE, INACTIVATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINATION; VACCINES; VACCINES, COMBINED;

EID: 77952667403     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11204830-000000000-00000     Document Type: Review

References (61)

1. World Health Organization. Immunization against disease of public health importance: fact sheet no.288 [online]. Available from URL: http://www.who.int/ mediacentre/factsheets/fs288/en/index.html [Accessed 2010 Mar 11]
2. United Nations Children's Fund. Immunization summary: a statistical reference containing data through 2008 (the 2010 edition) [online]. Available from URL: http://www. childinfo.org/files/Immunization-Summary-2008-r6.pdf [Accessed 2010 Mar 10]
3. Combination vaccines for childhood immunization: recom-mendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). Pediatrics 1999 May; 103 (5 Pt 1): 1064-1077
4. Mullany L. Considerations for implementing a new combi-nation vaccine into managed care. Am J Manag Care 2002; 9 (1 Suppl.): S23-9
5. Centers for Disease Control and Prevention. ACIP provi-sional recommendations for the use of combination vaccines [online]. Available from URL: http://www.cdc.gov/vaccines/recs/provisional/downloads/combo-vax-Aug2009- 508.pdf [Accessed 2010 Mar 11]
6. Zepp F, Schmitt HJ, Cleerbout J, et al. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 2009 Jun; 8 (6): 663-678
7. European Medicines Agency. Infanrix hexa: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/ humandocs/PDFs/EPAR/In fanrixhexa/H-296-PI-en.pdf [Accessed 2010 Apr 18]
8. Tichmann I, Preidel H, Grunert D, et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 2005 May 9; 23 (25): 3272-3279
9. Tichmann I, Grunert D, Habash S, et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination. Hum Vaccin 2006 Nov 31; 2 (6): 249-254
10. Kilpi TM, Silfverdal SA, Nilsson L, et al. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. Hum Vaccin 2009 Jan 28; 5 (1): 18-25
11. Aristegui J, Dal-Re R, Diez-Delgado J, et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine 2003 Sep 8; 21 (25-26): 3593-3600
12. European Medicines Agency recommends suspension of Hexavac [media release] 2005 Sep 20 [online]. Available from URL: http://www.ema.europa.eu/ humandocs/PDFs/EPAR/Hexavac/29736905en.pdf
13. Zepp F, Knuf M, Heininger U, et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 2004 Jun 2; 22 (17-18): 2226-2233
14. Avdicova M, Prikazsky V, Hudeckova H, et al. Immuno-genicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr 2002 Nov; 161 (11): 581-587
15. Tejedor JC, Omenaca F, Garcia-Sicilia J, et al. Antibody persistence after primary vaccination with a hexavalent DTPa-HBV-IPV/HiB vaccine coadministered with a me-ningococcal C-CRM197 vaccine and response to a DTPa-IPV/HiB booster at 18 months of age. Pediatr Infect Dis J 2006 Oct; 25 (10): 943-945
16. Gabutti G, Zepp F, Schuerman L, et al. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age. Scand J Infect Dis 2004; 36 (8): 585-592
17. Omenaca F, Garcia-Sicilia J, Boceta R, et al. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. Pediatr Infect Dis J 2007 Sep; 26 (9): 824-829
18. Pichichero ME, Blatter MM, Reisinger KS, et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J 2002 Sep; 21 (9): 854-859
19. Lim FS, Han HH, Jacquet JM, et al. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus in-fluenzae type B vaccine. Ann Acad Med Singapore 2007 Oct; 36 (10): 801-806
20. Zinke M, Kappes R, Kindler K, et al. Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin 2009 Sep; 5 (9): 592-598
21. Tejedor JC, Moro M, Ruiz-Contreras J, et al. Immuno-genicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-te-tanus toxoid conjugate vaccine. Pediatr Infect Dis J 2006 Aug; 25 (8): 713-720
22. Schmitt HJ, Knuf M, Ortiz E, et al. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr 2000 Sep; 137 (3): 304-312
23. Tejedor JC, Omenaca F, Garcia-Sicilia J, et al. Immuno-genicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influ-enzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J 2004 Dec; 23 (12): 1109-1115
24. Tichmann-Schumann I, Soemantri P, Behre U, et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal con-jugate vaccine. Pediatr Infect Dis J 2005 Jan; 24 (1): 70-77
25. Knuf M, Habermehl P, Cimino C, et al. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 2006 May 29; 24 (22): 4727-4736
26. Heininger U, Sanger R, Jacquet JM, et al. Booster im-munization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 2007 Jan 22; 25 (6): 1055-1063
27. World Health Organization. WHO position paper on Hae-mophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 2006; 81 (47): 445-452
28. Zinke M, Disselhoff J, Gartner B, et al. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Hum Vac-cin. Epub 2010 Feb 18; 6 (2)
29. Steiner M, Ramakrishnan G, Gartner B, et al. Lasting im-mune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life. BMC Infect Dis 2010; 10: 9
30. Giambi C, Bella A, Barale A, et al. A cohort study to eval-uate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis 2008 Jul 28; 8: 100
31. Nolan T, Altmann A, Skeljo M, et al. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine. Vaccine 2004 Nov 15; 23 (1): 14-20
32. Omenaca F, Garcia-Sicilia J, Garcia-Corbeira P, et al. Res-ponse of preterm newborns to immunization with a hex-avalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics 2005 Dec; 116 (6): 1292-1298
33. Omenaca F, Garcia-Sicilia J, Garcia-Corbeira P, et al. An-tipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine. Pediatrics 2007 Jan; 119 (1): e179-85
34. Vazquez L, Garcia F, Ruttimann R, et al. Immunogenicity and reactogenicity of DTPa-HBV-IPV/Hib vaccine as primary and booster vaccination in low-birth-weight premature infants. Acta Paediatr 2008 Sep; 97 (9): 1243-1249
35. Knuf M, Szenborn L, Moro M, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophi-lus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J 2009 Apr; 28 Suppl. 4: S97-S108
36. Zepp F, Behre U, Kindler K, et al. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. Eur J Pediatr 2007 Aug; 166 (8): 857-864
37. Vesikari T, Prymula R, Schuster V, et al. Rotarix™ (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diptheria-tetanus-pertussis (DTPa)-combined vaccines in healthy infants in Europe. 24th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2006 May 3-5; Basel
38. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of hu-man rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007 Nov 24; 370 (9601): 1757-1763
39. Esposito S, Tansey A, Thompson A, et al. Safety and im-munologic non-inferiority of 13-valent pneumococcal conjugate vacine given as a 3-dose series with routine vaccines in healthy children [abstract no. 258]. 27th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2009 Jun 9-13; Brussels
40. Kieninger DM, Kueper K, Steul K, et al. Safety and immunologic noninferiority of 13-valent pneumococcal conjugate vaccine compared to 7-valent pneumococcal conjugate vaccine given with routine vaccines in healthy infants [abstract no. 111]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting; 2008 October 25-28; Washington, DC
41. Gimenez-Sanchez F, Kieninger DM, Kueper K, et al. Immunogenicity of Infanrix hexa antigens when given concomitantly with 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers [abstract no. 109]. Infectious Diseases Society of America 47th Annual Meeting; 2009 Oct 29-Nov 1; Philadelphia (PA)
42. Kalies H, Grote V, Siedler A, et al. Effectiveness of hex-avalent vaccines against invasive Haemophilus influenzae type b disease: Germany's experience after 5 years of licensure. Vaccine 2008 May 12; 26 (20): 2545-2552
43. Schmitt HJ, von Konig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996 Jan 3; 275 (1): 37-41
44. Greco D, Salmaso S, Mastrantonio P, et al. on behalf of the Progetto Pertosse Working Group. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996 Feb 8; 334 (6): 341-348
45. Gustafsson L, Hessel L, Storsaeter J, et al. Long-term fol-low-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006 Sep; 118 (3): 978-984
46. Saenger R, Maechler G, Potreck M, et al. Booster vaccina-tion with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately. Vaccine 2005 Jan 19; 23 (9): 1135-1143
47. von Kries R, Toschke AM, Strassburger K, et al. Sudden and unexpected deaths after the administration of hexavalent vaccines (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilius influenzae type b): is there a signal? Eur J Pediatr 2005 Feb; 164 (2): 61-69
48. von Kries R. Comment on B. Zinka et al. Unexplained cases of sudden infant death shortly after hexavalent vaccination [letter]. Vaccine 2006 Jul 26; 24 (31-32): 5783-4; author reply 5785-5786
49. Chevallier B, Vesikari T, Brzostek J, et al. Safety and re-actogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J 2009 Apr; 28 (4 Suppl.): S109-18
50. World Health Organization. Hepatitis B [online]. Available from URL: http://www.who.int/csr/disease/hepatitis/He patitisB-whocdscsrlyo2002-2.pdf [Accessed 2010 Mar 16]
51. World Health Organization. Hepatitis B: fact sheet no.204 (revised Aug 2008) [online]. Available from URL: http://www.who.int/mediacentre/factsheets/ fs204/en/index.html [Accessed 2010 Mar 16]
52. Watt JP, Wolfson LJ, O'Brien KL, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009 Sep 12; 374 (9693): 903-911
53. EUVAC.NET. National childhood vaccination schedules [online]. Available from URL: http://www.euvac.net/gra phics/euvac/vaccination/vaccination.html [Accessed 2010 Mar 12]
54. Kalies H, Grote V, Verstraeten T, et al. The use of combi-nation vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006 Jun; 25 (6): 507-512
55. Public Health Agency of Canada. Immunization schedules for infants and children [online]. Available from URL: http://www.phac-aspc.gc.ca/im/is-cv/ index-eng.php [Accessed 2010 Mar 12]
56. Eskola J, Ward J, Dagan R, et al. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999 Dec 11; 354 (9195): 2063-2068
57. Pichichero ME. Booster vaccinations: can immunologic memory outpace disease pathogenesis? Pediatrics 2009; 124 (6): 1633-1641
58. Kalies H, Verstraeten T, Grote V, et al. Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Germany. Pediatr Infect Dis J 2004 Oct; 23 (10): 944-950
59. Juretzko P, von Kries R, Hermann C. Effectiveness of acel-lular pertussis vaccine assessed by hospital-based active su-veillance in Germany. Clin Infect Dis 2002 Jul; 35 (2): 162-167
60. World Health Organization. Global Advisory Committee on Vaccine Safety, 2-3 December 2004. Wkly Epidemiol Rec 2005 Jan 7; 80 (1): 3-7
61. World Health Organization. Global Advisory Committee on Vaccine Safety, 9-10 June 2005. Wkly Epidemiol Rec 2005 Jul 15; 80 (28): 242-247